1Kuang D, Verbine A, Ronco C, et al. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy [ J ]. Clin Nephrol, 2007,67 (5) :267 -284.
2Vincent HT, Lomacstro BM. Drug dosing in patients undergoing continuous renal replacement therapy[ J]. NY State J Healthsyst Pharmacist,2001,20 ( 1 ) : 10 - 14.
3Pinder M, Bellomo R, Lipman J, et al. Pharmacological principles of antibiotic prescription in the critically ill [ J ]. Anaesth Intensive Care,2002,30(2) : 134 - 144.
4Isla A, Gascon AR, Maynar J, et al. Cefepime and continuous renal replacement therapy (CRRT) : in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients[J]. Clin Ther,2005,27 (5) :599 - 608.
5Rebecca S, Malone, Douglas N, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically Ⅲ patients[ J]. Antimicrob Agents Chemother,2001,45 ( 11 ) : 3148 -3155.
6Douglas N,Fish ,Teitelbaum I, et al. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically Ⅲ patients[ J]. Antimicrob Agents Chemother,2005,49 (6) :2421 - 2428.
7Rebecca S, Malone, Douglas N, et al. Pharmacokinetics of Levo- floxacln and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ⅲ Patients[J]. Antimicrob Agents Chemother,2001,45 ( 10 ) : 2949 - 2954.
8Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration [ J ]. J Antimicrob Chemother,2007,60 (5) : 1085 - 1090.
10Arzuaga A,Maynar J, Alicia R, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive Care unit patients during continuous venovenous hemofiltration [ J]. J Clin Pharmacol,2005,45 (2) : 168 - 176.
7Chiu YW, Jiwakanon S, Lukowsky L, et al. An update on the comparisons of mortality outcomes of hemodialysis and peritoneal dialysis patients[J]. Semin Nephrol, 2011, 31(2): 152-158.
8Tai DJ, Lim TW, James MT, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis[J]. Clin J Am Soc Nephrel, 2010, 5(4): 623-630.
9Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coil Cardiol, 2014, 63(25 Pt B): 2889-2934.
